Business Context and Reporting Period
This Form 8-K was filed by Anavex Life Sciences Corp. on July 18, 2016. The report details an amendment to the employment agreement with Christopher Missling, PhD, the Company's Chief Executive Officer, effective July 18, 2016.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change is the clarification of stock option grants previously awarded to Dr. Missling on July 5, 2016. The amendment specifies the exact number of options and exercise prices, removing previous references to future option grants.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or general management commentary in this filing. The document serves to formalize the terms of the CEO's compensation package.
Executive Compensation Details
- Grant 1: 379,625 options at an exercise price of $6.26 per share. These options have a total value of $2,000,000 and vest quarterly over three years, commencing October 5, 2016.
- Grant 2: 861,429 options at an exercise price of $7.06 per share. These options vest quarterly over three years, commencing October 18, 2016.
Investor Verification Checklist
- Verify the total number of shares authorized for issuance under the Company's stock option plan to ensure these grants are covered.
- Review the full text of Exhibit 10.1 (Amended and Restated First Amendment to Employment Agreement) for additional terms not summarized here.
- Confirm the vesting schedule dates (October 5, 2016, and October 18, 2016) against the Company's fiscal calendar.
- Check subsequent filings for any changes to the exercise prices or vesting conditions.